Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

BioLine Tumbles Most on Record After Drug Fails in Study

BioLineRx Ltd. tumbled the most on record after an experimental treatment for schizophrenia failed to help patients in a mid-stage clinical trial, prompting the Israeli drugmaker to end development of the compound.

BioLine, based in Jerusalem, plunged 53 percent to $1.80 in New York, the lowest price since July 2011, when the shares were listed in the U.S. The Bloomberg Israel-US Equity Index of the biggest Israeli companies in the U.S. rose for the first time in four days, adding 1 percent.

The treatment, BL-1020, didn’t meet the trial’s main goal of improving cognitive function compared with risperidone, a generic drug, BioLine said in a statement. The American depositary receipts had gained 51 percent this year through yesterday. Shares in Tel Aviv dropped 52 percent to 6.82 shekels, or $1.85 today.

“For the stock price to be cut in half, in our view, seems excessive,” Raghuram Selvaraju, an analyst at New York-based Aegis Capital Corp., said in a phone interview. He cut his share-price estimate today by 36 percent to $7 and kept a buy rating on BioLine. “All the institutional investors I spoke with thought it would fail.”

The biopharmaceutical company said in the statement that research and development costs will drop this year and in part of 2014 by about $6 million to $7 million.

Schizophrenia is a disabling brain disorder, affecting about 1 percent of Americans, according to the National Institute of Mental Health.

Download: Earnings

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.